Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Century Therapeutics stock | $19.31

Learn how to easily invest in Century Therapeutics stock.

Century Therapeutics Inc. is a biotechnology business based in the US. Century Therapeutics shares (IPSC) are listed on the NASDAQ and all prices are listed in US Dollars. Century Therapeutics employs 121 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Century Therapeutics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – IPSC – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Century Therapeutics stock price (NASDAQ: IPSC)

Use our graph to track the performance of IPSC stocks over time.

Century Therapeutics shares at a glance

Information last updated 2021-10-10.
Latest market close$19.31
52-week range$17.53 - $32.90
50-day moving average $24.19
200-day moving average $26.45
Wall St. target price$36.25
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-8.14

Buy Century Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Century Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Century Therapeutics price performance over time

Historical closes compared with the close of $19.31 from 2021-10-15

1 week (2021-10-08) 8.91%
1 month (2021-09-17) -22.01%
3 months (2021-07-16) -29.93%
6 months (2021-04-13) N/A
1 year (2020-10-13) N/A
2 years (2019-10-13) N/A
3 years (2018-10-13) N/A
5 years (2016-10-13) N/A

Century Therapeutics financials

Gross profit TTM $0
Return on assets TTM 0%
Return on equity TTM 0%
Profit margin 0%
Book value $8.23
Market capitalisation $964.6 million

TTM: trailing 12 months

Shorting Century Therapeutics shares

There are currently 1.6 million Century Therapeutics shares held short by investors – that's known as Century Therapeutics's "short interest". This figure is 6.3% down from 1.7 million last month.

There are a few different ways that this level of interest in shorting Century Therapeutics shares can be evaluated.

Century Therapeutics's "short interest ratio" (SIR)

Century Therapeutics's "short interest ratio" (SIR) is the quantity of Century Therapeutics shares currently shorted divided by the average quantity of Century Therapeutics shares traded daily (recently around 154649.6124031). Century Therapeutics's SIR currently stands at 10.32. In other words for every 100,000 Century Therapeutics shares traded daily on the market, roughly 10320 shares are currently held short.

To gain some more context, you can compare Century Therapeutics's short interest ratio against those of similar companies.

However Century Therapeutics's short interest can also be evaluated against the total number of Century Therapeutics shares, or, against the total number of tradable Century Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Century Therapeutics's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Century Therapeutics shares in existence, roughly 30 shares are currently held short) or 0.1074% of the tradable shares (for every 100,000 tradable Century Therapeutics shares, roughly 107 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Century Therapeutics.

Find out more about how you can short Century Therapeutics stock.

Century Therapeutics share dividends

We're not expecting Century Therapeutics to pay a dividend over the next 12 months.

You may also wish to consider:

Century Therapeutics overview

Century Therapeutics, Inc. , a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT or CAR-iNK candidate targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia. Century Therapeutics, Inc. has a research collaboration with Outpace Bio, Inc. for CAR engineering.

Frequently asked questions

What percentage of Century Therapeutics is owned by insiders or institutions?
Currently 11.226% of Century Therapeutics shares are held by insiders and 41.184% by institutions.
How many people work for Century Therapeutics?
Latest data suggests 121 work at Century Therapeutics.
When does the fiscal year end for Century Therapeutics?
Century Therapeutics's fiscal year ends in December.
Where is Century Therapeutics based?
Century Therapeutics's address is: 3675 Market Street, Philadelphia, PA, United States, 19104
What is Century Therapeutics's ISIN number?
Century Therapeutics's international securities identification number is: US15673T1007

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site